TMEFF2 Antibody

What is the structure and tissue distribution of TMEFF2?

TMEFF2 is a 374-residue type-I transmembrane proteoglycan with a complex domain structure. Its N-terminus harbors a signal peptide followed by two follistatin-like domains and an EGF-like domain, with a transmembrane portion and a short intracellular domain . The protein exhibits restricted normal tissue expression, primarily in the brain and prostate . This limited distribution pattern makes it an attractive target for cancer-specific therapies, as it minimizes potential off-target effects in other tissues.

When designing experiments targeting TMEFF2, researchers should note that despite the presence of an EGF-like domain, this region appears to be functionally ineffective due to substitution of a crucial arginine residue (Arg39) with histidine, whereas the follistatin-like domains are reported to be crucial for TMEFF2's biological functions .

How does TMEFF2 expression in prostate cancer compare with other cancer types?

While TMEFF2 is prominently studied in prostate cancer, research has revealed complex expression patterns across various malignancies. TMEFF2 is downregulated in glioma and cotricotropinomas . Interestingly, TMEFF2 methylation increases with breast, colon, and gastric cancer progression, suggesting potential utility as a biomarker beyond prostate cancer . For researchers conducting comparative studies, it's important to assess both protein expression and methylation status of TMEFF2 across cancer types.

What techniques are recommended for validating anti-TMEFF2 antibodies?

Proper validation of anti-TMEFF2 antibodies is crucial for reliable experimental results. Based on published research, a comprehensive validation approach should include:

• Binding specificity assessment: Test antibody binding to TMEFF2-positive cell lines (e.g., LNCaP-AR) with TMEFF2-negative cell lines (e.g., DU145) as controls .

• Binding affinity determination: Measure EC50 values for binding to target cells (e.g., 9.6 nM for JNJ-902 binding to LNCaP-AR cells) .

• Cross-reactivity evaluation: Assess cross-reactivity with murine TMEFF2 if intended for preclinical models, as there is a high degree of homology (98.9% identity) between human and mouse orthologs .

• Immunohistochemistry validation: Use on clinical specimens with appropriate controls to confirm specific staining patterns .

• Functional assays: For therapeutic antibodies, assess T-cell activation or cytotoxicity in appropriate in vitro systems .

What are the considerations for developing bispecific antibodies targeting TMEFF2?

Development of bispecific antibodies targeting TMEFF2 requires careful design and validation. JNJ-70218902 (JNJ-902), a bispecific antibody targeting TMEFF2 and CD3, provides instructive examples of key considerations:

• Optimal binding affinity balancing: The binding affinity (KD) of JNJ-902 for CD3 on primary human T cells was determined to be ~151 nM, while the EC50 for TMEFF2-positive LNCaP-AR cells was 9.6 nM . This differential affinity is important for proper functioning of the bispecific construct.

• Functional validation: T cell-mediated killing should be confirmed through appropriate assays, such as caspase-3 activity measurement upon incubation with target cells and T cells (EC50 = 1.4 nM for JNJ-902) .

• Cytokine production assessment: Measure concentration-dependent increases in proinflammatory cytokine production (e.g., GM-CSF, IFN-γ, IL-10, TNF-α) to confirm immune activation .

• Specificity controls: Include TMEFF2-negative cell lines and control antibodies to confirm target specificity .

What in vitro models are most appropriate for evaluating anti-TMEFF2 antibody efficacy?

Based on the literature, researchers should consider the following cell models for in vitro evaluation of anti-TMEFF2 antibodies:

• TMEFF2-positive cell lines:

  • LNCaP and LNCaP-AR (androgen-sensitive human prostate cancer cell lines)

  • CWR22 prostate cancer cells

• TMEFF2-negative controls:

  • DU145 prostate cancer cells

• Experimental setups:

  • For antibody-drug conjugates: Cytotoxicity assays with target cells

  • For bispecific antibodies: Co-culture systems with target cells and T cells at defined effector:target ratios (e.g., 3:1)

  • Caspase-3 activity assays to measure cell death

  • Flow cytometry to assess T cell activation (CD8+CD25+ expression)

What preclinical animal models have been validated for anti-TMEFF2 antibody testing?

Several animal models have been validated for preclinical testing of anti-TMEFF2 antibodies:

• Xenograft mouse models:

  • Severe combined immunodeficient (SCID) mice bearing LNCaP and CWR22 human prostate cancer xenografts

  • T cell humanized NSG mice bearing LNCaP xenografts

  • LuCaP 86.2 patient-derived xenografts

• Non-human primate models:

  • Cynomolgus monkeys for pharmacodynamic studies of bispecific antibodies due to 100% sequence homology and analogous biodistribution of TMEFF2 compared to humans

Efficacy endpoints in these models typically include tumor growth inhibition (TGI) measurements, with reported values of 75-122% TGI in LNCaP xenografts and 72-88% TGI in patient-derived xenografts with JNJ-902 .

How do different anti-TMEFF2 antibody modalities compare in preclinical efficacy?

Research has explored multiple antibody-based therapeutic approaches targeting TMEFF2:

• Antibody-Drug Conjugates (ADCs):

  • Pr1-vcMMAE: Anti-TMEFF2 mAb conjugated to auristatin E via a cathepsin B-sensitive valine-citrulline linker

  • Doses of 3-10 mg/kg resulted in significant and sustained tumor growth inhibition in xenograft models

  • Similar efficacy observed with huPr1-vcMMAE, a humanized version

• Bispecific T-cell Redirecting Antibodies:

  • JNJ-70218902 (JNJ-902): Bispecific antibody engaging TMEFF2 on tumor cells and CD3 on T cells

  • Demonstrated antitumor activity at concentrations up to 5 mg/kg in T cell humanized NSG mice bearing LNCaP xenografts

  • Induced intratumoral infiltration of CD8+ T cells with increases in CD8+granzymeB+ effector cells

Both approaches show promising preclinical efficacy, but they operate through different mechanisms - direct delivery of cytotoxic agents versus T cell-mediated killing - which may have implications for different disease contexts.

What biomarkers should be monitored in TMEFF2-targeting clinical trials?

Based on preclinical studies, researchers conducting clinical trials with TMEFF2-targeting antibodies should consider monitoring:

• Target engagement markers:

  • TMEFF2 expression levels in tumor biopsies via IHC

  • Methylation status of TMEFF2 promoter

• Pharmacodynamic biomarkers (particularly for bispecific antibodies):

  • T cell infiltration in tumor biopsies (CD4+ and CD8+ T cells)

  • T cell activation markers (granzyme B, CD25, CD69, Ki-67)

  • Immunosuppressive markers (CD4+CD25hi Foxp3+)

  • Inflammatory cell infiltration (dendritic cells, myeloid cells, macrophages, B cells)

  • Proinflammatory cytokine levels (GM-CSF, IFN-γ, IL-10, TNF-α)

How do researchers reconcile contradictory findings about TMEFF2's role in cancer?

The literature reveals apparently contradictory findings regarding TMEFF2's role in cancer biology:

• Oncogenic vs. Tumor-Suppressive Function: TMEFF2 appears to have both oncogenic and tumor-suppressive roles, particularly in prostate cancer . This apparent contradiction may be due to:

  • Context-dependent functions in different cancer stages or subtypes

  • Different functional domains of the protein having opposing effects

  • Differences between full-length protein versus shed ectodomain activities

• Methylation Patterns: While TMEFF2 is overexpressed in prostate cancer, its promoter is hypermethylated in other cancers, suggesting different regulatory mechanisms across cancer types .

Researchers should carefully consider these contradictions when designing experiments and interpreting results. Comprehensive approaches examining both expression and functional effects in well-defined model systems are recommended.

What are the key limitations of current TMEFF2-targeting therapeutic approaches?

Current limitations of TMEFF2-targeting therapeutics include:

• Dose-limiting toxicities: In clinical studies with JNJ-902, dose escalation was limited by emerging dose-limiting toxicities, preventing determination of a recommended phase II dose .

• Lack of clear exposure-response relationship: Clinical studies showed no clear exposure-response relationship for JNJ-902, complicating dose optimization .

• Limited efficacy in heavily pretreated patients: The efficacy of immunotherapeutic approaches may be compromised in heavily pretreated mCRPC patients who have received chemotherapy and corticosteroids, which can impact immune system function .

• Heterogeneity of mCRPC: The heterogeneous nature of mCRPC suggests that immunotherapy may be effective only in certain patient subsets, highlighting the need for better patient selection biomarkers .

• Brain expression concerns: TMEFF2 expression in normal brain tissue raises potential concerns about central nervous system toxicity that require careful monitoring in clinical development .

What novel applications of TMEFF2 antibodies are emerging beyond oncology?

While TMEFF2 antibodies have primarily been investigated for cancer therapy, emerging research suggests potential applications in other areas:

• Neurodegenerative diseases: TMEFF2 binds amyloid β protein, its precursor, and derivatives, providing neuroprotection in Alzheimer's disease . This suggests potential diagnostic or therapeutic applications of anti-TMEFF2 antibodies in neurodegenerative conditions.

• Diagnostic applications: Detection of methylated free-circulating TMEFF2 DNA has been suggested as a potential diagnostic tool for breast and colorectal cancer .

• Endocrine disorders: TMEFF2's role in corticotropin release hormone (CRH) stimulation in the anterior pituitary gland suggests potential applications in certain endocrine disorders .

What are the most promising approaches to overcome current limitations in TMEFF2-targeted therapies?

To address current limitations of TMEFF2-targeted therapies, researchers are exploring several approaches:

• Alternative dosing regimens: Step-up dosing approaches (e.g., 0.075 mg/kg followed by 0.3 mg/kg one week later) have shown promise in preclinical models with potential to mitigate toxicity while maintaining efficacy .

• Biomarker-guided patient selection: Identification of biomarkers that correlate with response to T-cell redirectors may help guide patient selection and improve outcomes .

• Combination therapies: Exploring combinations with other immunotherapies or standard-of-care treatments may enhance efficacy while managing toxicity profiles.

• Enhanced antibody engineering: Development of next-generation antibody formats with improved pharmacokinetics, tissue penetration, or controllable activity may address current limitations.

• Better characterization of TMEFF2 biology: Further investigations into the biological and pathological functions of TMEFF2 are necessary to optimize therapeutic targeting strategies .